

Regarding the Transparency Guideline for the Relation between Corporate Activities and Medical Institutions

The members of The Japan Pharmaceutical Manufacturers Association are making efforts to improve the transparency/reliability of the relation between corporate activities and medical institutions with cooperation from medical institutions and medical professionals.

The pharmaceutical industry is closely associated with the lives and health of patients and people, and thus, securing transparency and fulfilling accountability are required more for the activities of these industries, compared to other industries, under the national health insurance of the nation of Japan. On the other hand, conflicts of interest occur in some cases in industry-academia collaboration between the pharmaceutical companies and medical institutions or medical professionals, which are essential for delivering optimal pharmaceutical products to patients.

“Appropriate management of the conflicts of interest” and “actions to improve transparency for the relation between the pharmaceutical companies and medical institutions or medical professionals” will be indispensable to make activities of the pharmaceutical companies reliable ethically and in a trustworthy manner, placing a priority on the health of the patients.

Considering the above, The Japan Pharmaceutical Manufacturers Association (hereinafter “JPMA”) prepared in 2011 the “the Transparency Guideline for the Relation between Corporate Activities and Medical Institutions” (hereinafter this “Guideline”) and has publicly disclosed the funds, etc. pertaining to industry-academia collaborative activities with understanding and cooperation from medical institutions and medical professionals.

We believe that efforts which have been promoted by the government agencies concerned and each organization for management of the conflicts of interest and the publication of funds, etc. by member companies of JPMA in accordance with this Guideline would lead to increased confidence in industry-academia collaboration.

JPMA will continue to review this Guideline based on feedback from various sources to further improve transparency and reliability.

We hope that the medical institutions and medical professionals will kindly understand the purpose of this Guideline and provide their cooperation.

Japan Pharmaceutical Manufacturers Association

1. Purpose

The purpose of this Guideline is to gain a wide understanding of the pharmaceutical industry's contribution to life sciences, such as medicine and pharmacy, and for corporate activities to be conducted with high ethical standards, by making the relation between member companies' activities and medical institutions, etc. transparent.

Each member company shall prepare its own in-house "Policy for Transparency" as a code of practice, referring to this Guideline.

2. Contents of publication

(1) Disclosure method

The payments, etc. shall be disclosed through each company's own website.

(2) Timing of disclosure

The payments, etc. shall be disclosed within one (1) year after conclusion of each fiscal year of each company.

(3) Targets of disclosure

The payments, etc. in the previous fiscal year shall be disclosed in accordance with each item below.

A. Research and development expenses, etc.

Research and development expenses, etc. include expenses required for research/surveillance, etc. conducted under public regulations and various policies such as the Clinical Trials Act and GCP/GVP/GPSP ordinances under the Pharmaceutical and Medical Device Act.

Funds, etc. provided shall be disclosed as follows together with the annual total amount of each item.

- | | |
|---|--|
| • Specified clinical trial expenses (Note 1) | Name, etc. of the relevant institution, etc. (Note 2): Number of cases, XX yen |
| • Research expenses based on ethical guidelines (Note 3) | Name of the relevant institution, etc. (Note 4): Number of cases, XX yen |
| • Research expenses other than clinical trials (Note 5) | Annual number of cases/total amount, name of the relevant institution, etc. |
| • Clinical trial expenses | Name of the relevant institution, etc. (Note 4): Number of cases, XX yen |
| • Post-marketing clinical study expenses | Name of the relevant institution, etc. (Note 4): Number of cases, XX yen |
| • Adverse drug reaction/infection case reporting expenses | Name of the relevant institution, etc. (Note 4): Number of cases, XX yen |
| • Post-marketing surveillance expenses | Name of the relevant institution, etc. (Note 4): Number of cases, XX yen |
| • Other expenses | Annual total amount |

(Note 1) "Specified clinical trial expenses" refer to expenses paid pursuant to a contract for a specified clinical trial as defined in the Clinical Trials Act.

(Note 2) "Clinical trial identification number", "institution, etc. to which funds are provided", "name of sponsor", "name of medical institution conducting the research" and "name of principal investigator", etc. shall be disclosed.

(Note 3) "Ethical guidelines" as used for the "research expenses based on ethical guidelines" shall mean the "Ethical Guidelines for Medical and Biological Research Involving Human Subjects" (life/medical and health guidelines).

(Note 4) For "name of the relevant institution, etc.", "name of the institution", "name of in-house

D. Information provision-related expenses

Expenses of lecture meetings and explanation meetings, etc. for providing information, etc. related to the company's pharmaceutical products, medicine and pharmacy to medical professionals.

- Expenses for meetings including Annual number of meetings and total amount
lectures, etc.
- Explanation meeting expenses Annual number of meetings and total amount
- Medical/pharmaceutical Annual total amount
literature, etc. supply expenses

E. Other expenses

Expenses for hospitality, etc. as social courtesy

- Expenses for hospitality, etc. Annual total amount

68 member companies (as of April 2026)

Asahi Kasei Therapeutics Corporation	SANWA KAGAKU KENKYUSHO CO., LTD.	Nippon Zoki Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd.	JCR Pharmaceuticals Co., Ltd.	Nippon Boehringer Ingelheim Co., Ltd.
Astellas Pharma Inc.	Shionogi & Co., Ltd.	Novartis Pharma K.K.
AstraZeneca K.K.	Sumitomo Pharma CO., LTD.	Novo Nordisk Pharma Ltd.
AbbVie G.K.	SEIKAGAKU CORPORATION	Bayer Yakuhin, Ltd.
Amgen Inc.	ZERIA Pharmaceutical Co., Ltd.	Biogen Japan Ltd.
Alfresa Pharma Corporation	Senju Pharmaceutical Co., Ltd.	Research Institute for Microbial Diseases
EA Pharma Co., Ltd.	Daiichi Sankyo Co., Ltd.	Hisamitsu Pharmaceutical Co., Inc.
Viatrix Pharmaceuticals Japan G.K.	Taisho Pharmaceutical Co., Ltd.	Pfizer Japan Inc.
Eisai Co., Ltd.	TAIHO PHARMACEUTICAL Co., Ltd.	Fuji Pharma Co., Ltd.
MSD K.K.	Takeda Pharmaceutical Company Limited	FUJIFILM Toyama Chemical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.	Tanabe Pharma Corporation	Fujimoto Pharmaceutical Corporation
Ono Pharmaceutical Co., Ltd.	Chugai Pharmaceutical Co., Ltd.	Fuso Pharmaceutical Industries, Ltd.
Kaken Pharmaceutical Co., Ltd.	Tsumura & Co.	Bristol-Myers Squibb Company
Kissei Pharmaceutical Co., Ltd.	Teikoku Seiyaku Co., Ltd.	Maruishi Pharmaceutical Co., Ltd.
Kyoto Pharmaceutical Industries, Ltd.	TEIJIN PHARMA LIMITED	Maruho Co., Ltd.
KYORIN Pharmaceutical Co., Ltd.	TOA EIYO LTD.	Meiji Seika Pharma Co., Ltd.
Kyowa Kirin Co., Ltd.	Torii Pharmaceutical Co., Ltd.	Merck Biopharma Co., Ltd.
GlaxoSmithKline K.K.	Eli Lilly Japan K.K.	MOCHIDA PHARMACEUTICAL CO., LTD.
Kracie Pharma, Ltd.	Nippon Kayaku Co., Ltd.	Janssen Pharmaceutical K.K.
KM Biologics Co., Ltd.	Nippon Chemiphar Co., Ltd.	UCB Japan Co., Ltd.
Kowa Company, Ltd.	NIPPON SHINYAKU CO., LTD.	Wakamoto Pharmaceutical Co., Ltd.
Sanofi K.K.		
Santen Pharmaceutical Co., Ltd.		

Japan Pharmaceutical Manufacturers Association

Nihonbashi Life Science Bldg.

2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023

TEL.03-3241-0326

FAX.03-3242-1767

<http://www.jpma.or.jp>